Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter
Cytokines might be involved in the immunological flare up, seen in some patients after 131I-treatment. Therefore, we measured serum levels of interleukin-6 (IL-6), interleukin-1beta (IL-1beta), interleukin-6 soluble receptor (IL-6sR) and Intercellular-adhesion-molecule-1 (ICAM-1) as well as tumor ne...
Gespeichert in:
| Veröffentlicht in: | Hormone and metabolic research 2000-07, Vol.32 (7), p.283 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 283 |
| container_title | Hormone and metabolic research |
| container_volume | 32 |
| creator | Nygaard, B Jarløv, A E Kristensen, L O Faber, J |
| description | Cytokines might be involved in the immunological flare up, seen in some patients after 131I-treatment. Therefore, we measured serum levels of interleukin-6 (IL-6), interleukin-1beta (IL-1beta), interleukin-6 soluble receptor (IL-6sR) and Intercellular-adhesion-molecule-1 (ICAM-1) as well as tumor necrosis factor (TNF-alpha) after 131I-treatment of Graves' disease and nodular goiter. Seven patients with Graves' disease, eight with toxic nodular goiter and seven with non-toxic nodular goiter, were followed after 131I-treatment. The patients were treated in the euthyroid state. Blood samples were drawn at day 0, 4, 7, 21 and after 3 months. Significant increases were seen in free T4 index (FT4I), free T3 index (FT3I) and thyroglobulin (Tg) within the first weeks, and TSH simultaneously decreased. None of the cytokines demonstrated any change during follow-up, neither in the entire group nor in subgroups. FT4I and FT3I correlated significantly to ICAM-1. In conclusion, our data suggest that there does not seem to be prolonged cytokine activation after 131I-treatment for thyroid disorders. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_10965935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10965935</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-e8c011f1bc37a0b2e96233e454070f4bf0f42a6950cc588f6e3e9e9f0896c6a03</originalsourceid><addsrcrecordid>eNo1jztPwzAUhT2AaCn8BeSNBUt2_Gg8ogpKpCAGulc3zjUE8pLtVOq_J6WwnMfwHelckCXnImeaK7kg1zF-zVVZoa7IQnBrtJV6ScI7hqmjLR6wjXTwNH0idcc0fDc9RlqUTFSY4OGUDIW-psXm8ZUJCj5hoEKKgqWAkDrs04nfBjhgvKd1ExEi_iL9UE8tBPoxNDN0Qy49tBFv_3xFds9Pu80LK9-283jJRq00w9xxIbyonFwDrzK0JpMSlVZ8zb2q_CwZGKu5czrPvUGJFq3nuTXOAJcrcneeHaeqw3o_hqaDcNz_f5c_3gFSgg</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Nygaard, B ; Jarløv, A E ; Kristensen, L O ; Faber, J</creator><creatorcontrib>Nygaard, B ; Jarløv, A E ; Kristensen, L O ; Faber, J</creatorcontrib><description>Cytokines might be involved in the immunological flare up, seen in some patients after 131I-treatment. Therefore, we measured serum levels of interleukin-6 (IL-6), interleukin-1beta (IL-1beta), interleukin-6 soluble receptor (IL-6sR) and Intercellular-adhesion-molecule-1 (ICAM-1) as well as tumor necrosis factor (TNF-alpha) after 131I-treatment of Graves' disease and nodular goiter. Seven patients with Graves' disease, eight with toxic nodular goiter and seven with non-toxic nodular goiter, were followed after 131I-treatment. The patients were treated in the euthyroid state. Blood samples were drawn at day 0, 4, 7, 21 and after 3 months. Significant increases were seen in free T4 index (FT4I), free T3 index (FT3I) and thyroglobulin (Tg) within the first weeks, and TSH simultaneously decreased. None of the cytokines demonstrated any change during follow-up, neither in the entire group nor in subgroups. FT4I and FT3I correlated significantly to ICAM-1. In conclusion, our data suggest that there does not seem to be prolonged cytokine activation after 131I-treatment for thyroid disorders.</description><identifier>ISSN: 0018-5043</identifier><identifier>PMID: 10965935</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Autoantibodies - blood ; Female ; Goiter, Nodular - blood ; Goiter, Nodular - radiotherapy ; Graves Disease - blood ; Graves Disease - radiotherapy ; Humans ; Intercellular Adhesion Molecule-1 - blood ; Interleukin-1 - blood ; Interleukin-6 - blood ; Iodine Radioisotopes - therapeutic use ; Male ; Middle Aged ; Thyroglobulin - blood ; Thyrotropin - blood ; Thyroxine - blood ; Triiodothyronine - blood</subject><ispartof>Hormone and metabolic research, 2000-07, Vol.32 (7), p.283</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10965935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nygaard, B</creatorcontrib><creatorcontrib>Jarløv, A E</creatorcontrib><creatorcontrib>Kristensen, L O</creatorcontrib><creatorcontrib>Faber, J</creatorcontrib><title>Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter</title><title>Hormone and metabolic research</title><addtitle>Horm Metab Res</addtitle><description>Cytokines might be involved in the immunological flare up, seen in some patients after 131I-treatment. Therefore, we measured serum levels of interleukin-6 (IL-6), interleukin-1beta (IL-1beta), interleukin-6 soluble receptor (IL-6sR) and Intercellular-adhesion-molecule-1 (ICAM-1) as well as tumor necrosis factor (TNF-alpha) after 131I-treatment of Graves' disease and nodular goiter. Seven patients with Graves' disease, eight with toxic nodular goiter and seven with non-toxic nodular goiter, were followed after 131I-treatment. The patients were treated in the euthyroid state. Blood samples were drawn at day 0, 4, 7, 21 and after 3 months. Significant increases were seen in free T4 index (FT4I), free T3 index (FT3I) and thyroglobulin (Tg) within the first weeks, and TSH simultaneously decreased. None of the cytokines demonstrated any change during follow-up, neither in the entire group nor in subgroups. FT4I and FT3I correlated significantly to ICAM-1. In conclusion, our data suggest that there does not seem to be prolonged cytokine activation after 131I-treatment for thyroid disorders.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Autoantibodies - blood</subject><subject>Female</subject><subject>Goiter, Nodular - blood</subject><subject>Goiter, Nodular - radiotherapy</subject><subject>Graves Disease - blood</subject><subject>Graves Disease - radiotherapy</subject><subject>Humans</subject><subject>Intercellular Adhesion Molecule-1 - blood</subject><subject>Interleukin-1 - blood</subject><subject>Interleukin-6 - blood</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Thyroglobulin - blood</subject><subject>Thyrotropin - blood</subject><subject>Thyroxine - blood</subject><subject>Triiodothyronine - blood</subject><issn>0018-5043</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jztPwzAUhT2AaCn8BeSNBUt2_Gg8ogpKpCAGulc3zjUE8pLtVOq_J6WwnMfwHelckCXnImeaK7kg1zF-zVVZoa7IQnBrtJV6ScI7hqmjLR6wjXTwNH0idcc0fDc9RlqUTFSY4OGUDIW-psXm8ZUJCj5hoEKKgqWAkDrs04nfBjhgvKd1ExEi_iL9UE8tBPoxNDN0Qy49tBFv_3xFds9Pu80LK9-283jJRq00w9xxIbyonFwDrzK0JpMSlVZ8zb2q_CwZGKu5czrPvUGJFq3nuTXOAJcrcneeHaeqw3o_hqaDcNz_f5c_3gFSgg</recordid><startdate>200007</startdate><enddate>200007</enddate><creator>Nygaard, B</creator><creator>Jarløv, A E</creator><creator>Kristensen, L O</creator><creator>Faber, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200007</creationdate><title>Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter</title><author>Nygaard, B ; Jarløv, A E ; Kristensen, L O ; Faber, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-e8c011f1bc37a0b2e96233e454070f4bf0f42a6950cc588f6e3e9e9f0896c6a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Autoantibodies - blood</topic><topic>Female</topic><topic>Goiter, Nodular - blood</topic><topic>Goiter, Nodular - radiotherapy</topic><topic>Graves Disease - blood</topic><topic>Graves Disease - radiotherapy</topic><topic>Humans</topic><topic>Intercellular Adhesion Molecule-1 - blood</topic><topic>Interleukin-1 - blood</topic><topic>Interleukin-6 - blood</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Thyroglobulin - blood</topic><topic>Thyrotropin - blood</topic><topic>Thyroxine - blood</topic><topic>Triiodothyronine - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nygaard, B</creatorcontrib><creatorcontrib>Jarløv, A E</creatorcontrib><creatorcontrib>Kristensen, L O</creatorcontrib><creatorcontrib>Faber, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Hormone and metabolic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nygaard, B</au><au>Jarløv, A E</au><au>Kristensen, L O</au><au>Faber, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter</atitle><jtitle>Hormone and metabolic research</jtitle><addtitle>Horm Metab Res</addtitle><date>2000-07</date><risdate>2000</risdate><volume>32</volume><issue>7</issue><spage>283</spage><pages>283-</pages><issn>0018-5043</issn><abstract>Cytokines might be involved in the immunological flare up, seen in some patients after 131I-treatment. Therefore, we measured serum levels of interleukin-6 (IL-6), interleukin-1beta (IL-1beta), interleukin-6 soluble receptor (IL-6sR) and Intercellular-adhesion-molecule-1 (ICAM-1) as well as tumor necrosis factor (TNF-alpha) after 131I-treatment of Graves' disease and nodular goiter. Seven patients with Graves' disease, eight with toxic nodular goiter and seven with non-toxic nodular goiter, were followed after 131I-treatment. The patients were treated in the euthyroid state. Blood samples were drawn at day 0, 4, 7, 21 and after 3 months. Significant increases were seen in free T4 index (FT4I), free T3 index (FT3I) and thyroglobulin (Tg) within the first weeks, and TSH simultaneously decreased. None of the cytokines demonstrated any change during follow-up, neither in the entire group nor in subgroups. FT4I and FT3I correlated significantly to ICAM-1. In conclusion, our data suggest that there does not seem to be prolonged cytokine activation after 131I-treatment for thyroid disorders.</abstract><cop>Germany</cop><pmid>10965935</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0018-5043 |
| ispartof | Hormone and metabolic research, 2000-07, Vol.32 (7), p.283 |
| issn | 0018-5043 |
| language | eng |
| recordid | cdi_pubmed_primary_10965935 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Adult Aged Aged, 80 and over Autoantibodies - blood Female Goiter, Nodular - blood Goiter, Nodular - radiotherapy Graves Disease - blood Graves Disease - radiotherapy Humans Intercellular Adhesion Molecule-1 - blood Interleukin-1 - blood Interleukin-6 - blood Iodine Radioisotopes - therapeutic use Male Middle Aged Thyroglobulin - blood Thyrotropin - blood Thyroxine - blood Triiodothyronine - blood |
| title | Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A26%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20levels%20of%20the%20cytokines%20IL-1beta,%20IL-6%20and%20ICAM-1%20after%20131I-treatment%20of%20Graves'%20disease%20and%20nodular%20goiter&rft.jtitle=Hormone%20and%20metabolic%20research&rft.au=Nygaard,%20B&rft.date=2000-07&rft.volume=32&rft.issue=7&rft.spage=283&rft.pages=283-&rft.issn=0018-5043&rft_id=info:doi/&rft_dat=%3Cpubmed%3E10965935%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10965935&rfr_iscdi=true |